USPTO serial 79453338
BIODELPHIS THERAPEUTICS
Reviewed by CopyMark Law Group
Status 641Office Action
- Filing date
- Status date
- Registration date
- —
- Examiner
- ALESKOW, DAVID HOWARD
- Law office
- TMEG LAW OFFICE 105
What this means
The USPTO has issued an Office Action on this application. A response is typically required before the deadline, or the application can be abandoned.
Need help with BIODELPHIS THERAPEUTICS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Office Action, set up monitoring, or talk with CopyMark.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Jaron Bentley
Jaron Bentley Daymark Legal2701 Cambridge CourtAuburn Hills, MI 48326United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations, namely antibody-peptide inhibitor conjugates intended for use in oncology as well as for the treatment of osteoporosis and autoimmune diseases; Dietary supplements for humans; all of the foregoing, excluding pharmaceutical or biotechnological preparations intended for genetic or neurological diagnosis or treatment, or involving genetic engineering, DNA manipulation, or drug delivery systems based on nanotechnology | ACTIVE | — |
| 035 | Retail or wholesale services for pharmaceutical, biotechnological and veterinary preparations as well as for medical supplies; all of the foregoing, with the exception of retail, wholesale or consulting services concerning diagnostic medical devices, genetic testing reagents or equipment intended for neurological research or diagnosis | ACTIVE | — |
| 040 | Processing and manufacturing of biochemical and pharmaceutical products for third parties and related consulting services; custom manufacturing of pharmaceutical products to order and according to a client's specifications; all of the foregoing, with the exception of services involving DNA sequencing, gene cloning, genetic modification of cells or nanotechnological processes intended for administering therapeutic agents | ACTIVE | — |
| 042 | Research and development for the pharmaceutical industry; research and development in the field of biotechnology; biotechnology research; research in biotechnology; biomedical research services; pharmaceutical research and development services; medical research services; scientific research services for medical purposes; scientific and technological services, as well as related research and development services; all of the above, excluding medical or clinical research in the field of genetic or neurological diseases, as well as services related to genetic engineering, DNA manipulation, or drug delivery using nanotechnology | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 30, 2026 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Sep 30, 2026 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Aug 6, 2026 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Aug 6, 2026 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 6, 2026 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Aug 6, 2026 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Aug 6, 2026 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Jul 25, 2026 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jul 24, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 24, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 23, 2026 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jul 23, 2026 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 17, 2026 | LIMI | LIMITATION FROM ORIGINAL APPLICATION ENTERED | — |
| Jul 2, 2026 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |